Autonomic Technologies announces Olivier Litzka and Martien van Osch to the Board after closing $38m series D financing round led by EdRIP

Funding Rounds

▤ Summary

“We are now well financed to further build out our leadership position in the growing field of neurostimulation in headache, expanding our launch to other countries in Europe and expanding the clinical evidence base of our minimally invasive treatment into other indications.” “Interested in and following the extremely dynamic field of neuromodulation/neurostimulation we were attracted to Autonomic Technologies Inc and its Pulsante microstimulator through very convincing clinical data in cluster headache, a disease of extreme pain with limited treatment options” said Olivier Litzka, Partner at EdRIP, “With ATI showing that it is able to professionally commercialize Pulsante in Europe, it makes it a very suitable investment for EdRIP.” “Pulsante microstimulator has already convinced many KOLs and patients in Europe and the US, and we therefore see a significant market potential for this treatment solution, which is brought forward by a very strong and experienced team.” added Martien van Osch, Managing Partner at Forbion. KPCB offers entrepreneurs years of operating experience, puts them at the center of a vast and influential network, and accelerates their success through expertise and support in recruiting, product design and delivery, business development, strategic partnerships and brandbuilding. As a financially driven corporate life science investor, the Novartis Venture Funds invest in those companies which have the potential to lead the next innovation wave in our core therapeutic fields or explore new business areas that will be critical to patient care. The firm has attracted and partnered with many superior early stage companies such as Ironwood, Pharmion, Clovis Oncology and MC10, repeatedly backing start-up’s that have grown to values exceeding $1 billion. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation.

$ Funding

$
Amount $38.0M Total raised
□
Date May 12, 2015 Announcement date
◎
Investors Novartis Venture Fund, Edmond de Rothschild, Aberdare Ventures Lead investors
▥
Company http://www.ati-spg.com Funded company

▥ Classifications

industries
HealthTech
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies